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Abstract
Introduction: The HIV protease inhibitor nelfinavir is currently under investigation as a new anti-cancer drug. Several 
studies have shown that nelfinavir induces cell cycle arrest, endoplasmic reticulum stress, autophagy, and apoptosis in 
cancer cells. In the present article, the effect of nelfinavir on human breast cancer cells is examined and potential 
combination treatments are investigated.
Methods: The effects of nelfinavir and tamoxifen on the human breast cancer cell lines MCF7, T47 D, MDA-MB-453, and 
MDA-MB-435 were tested by analysing their influence on cell viability (via 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay), apoptosis (annexin binding, poly(ADP-ribose) polymerase cleavage), autophagy 
(autophagy marker light chain 3B expression), endoplasmic reticulum stress (binding protein and activating 
transcription factor 3 expression), and the occurrence of oxidative stress (intracellular glutathione level).
Results: Nelfinavir induced apoptosis in all four breast cancer cell lines tested, although the extent of autophagy and 
endoplasmic reticulum stress varied among the cell lines. The concentration of nelfinavir needed for an efficient 
induction of apoptosis in breast cancer cells could be reduced from 15 μg/ml to 6 μg/ml when combined with 
tamoxifen. At a concentration of 6 μg/ml, tamoxifen substantially enhanced the endoplasmic reticulum stress reaction 
in those cell lines that responded to nelfinavir with binding protein (BiP) upregulation (MCF7, T47D), and enhanced 
autophagy in cell lines that responded to nelfinavir treatment with autophagy marker light chain 3B upregulation 
(MDA-MB-453). Although tamoxifen has been described to be able to induce oxidative stress at concentrations similar 
to those applied in this study (6 μg/ml), we observed that nelfinavir but not tamoxifen reduced the intracellular 
glutathione level of breast cancer cells within hours of application by up to 32%, suggesting the induction of oxidative 
stress was an early event and an additional cause of the apoptosis induced by nelfinavir.
Conclusions: The results demonstrate that nelfinavir may be an effective drug against breast cancer and could be 
combined with tamoxifen to enhance its efficacy against breast cancer cells. Moreover, the cytotoxic effect of a 
tamoxifen and nelfinavir combination was independent of the oestrogen receptor status of the analysed breast cancer 
cells, suggesting a potential benefit of a combination of these two drugs even in patients with no hormone-responsive 
tumours. We therefore recommend that clinical studies on nelfinavir with breast cancer patients should include this 
drug combination to analyse the therapeutic efficacy as well as the safety and tolerability of this potential treatment 
option.
Introduction
Breast cancer is the most frequent cancer in the female
population [1]. Although tremendous progress in the
treatment of breast cancer has been achieved during past
decades, it is still the principal cause of cancer death for
females worldwide [1,2].
Tamoxifen is a selective oestrogen receptor antagonist,
and since its introduction in cancer therapy has become
the standard treatment option for hormone-responsive
breast cancer patients [2-5]. Not all breast cancer
patients, however, benefit from an endocrine therapy
with tamoxifen [3]. Interestingly, several hormone recep-
tor-independent effects of tamoxifen have been
described, leading to apoptosis when higher concentra-
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tions of tamoxifen are applied [6,7]. A combination ther-
apy of tamoxifen with other drugs that cause synergistic
anti-tumour effects might therefore be an interesting
option in the therapy of breast carcinomas.
Nelfinavir (Viracept®; Pfizer, Groton, CT, USA) is an
HIV protease inhibitor that has long been an essential
component of the antiviral combination highly active
antiretroviral therapy. Several recent in vitro studies have
indicated that nelfinavir has potential anti-tumoral
effects [8,9], and clinical studies on nelfinavir are ongoing
to confirm its efficacy against human cancers in vivo [10-
13]. Nelfinavir exerts pleiotropic effects on cancer cells,
including induction of apoptosis, necrosis, and autophagy
[9,14,15]. Nelfinavir is believed to either cross-react with
a protease of the cytoplasmic proteasomal protein degra-
dation machinery or with endoplasmic reticulum-resi-
dent proteases [15,16]. In both cases, this protease
inhibition can lead to the accumulation of misfolded pro-
teins that cause the unfolded protein response or endo-
plasmic reticulum stress response [17-19]. These
pathways are primarily associated with a transient cell
cycle arrest and upregulation of molecular chaperones
such as binding protein (BiP) and other members of the
heat shock family, in order to repair and prevent further
cell damage [18]. A prolonged or irreparable stress reac-
tion, however, eventually switches from a repair and sur-
vival mechanism to cell death executed by apoptosis
[20,21]. This nonclassical cell death mechanism has
recently become of interest because of its ability to act
even on otherwise chemoresistant human cancer cells
[15,22].
Since the orally available drugs tamoxifen and nelfina-
vir have anti-tumoral properties, a combination of these
medications might be an intriguing option in the therapy
of breast cancer patients. However, no data regarding
their potential synergistic effects are yet available. We
therefore tested the effect of nelfinavir and tamoxifen
with regard to the influence on apoptosis, endoplasmic
reticulum stress, autophagy, and oxidative stress in breast
cancer cells with different oestrogen receptor status.
Materials and methods
Cells and cell culture
The breast cancer cell lines T47 D (ATCC HTB 133;
oestrogen receptor-positive), MCF7 (ATCC HTB 22;
oestrogen receptor-positive), MDA-MB-453 (ATCC HTB
131; oestrogen receptor-negative), and MDA-MB-435 S
(ATCC HTB 129; oestrogen receptor-negative) - all
kindly provided by G Saretzki (Newcastle, UK) - were
cultured in RPMI-1640 medium supplemented with 10%
foetal calf serum and antibiotics at 37°C in a humidified
atmosphere with 5% CO2. All cell culture reagents were
from PAA (Pasching, Austria).
Drugs and drug treatment
Nelfinavir (Viracept®) was generously provided by Pfizer.
Nelfinavir was dissolved in ethanol and kept at -20°C as a
100 mg/ml stock solution. Tamoxifen (Sigma, Munich,
Germany) was dissolved in dimethylsulfoxide at a con-
centration of 100 mg/ml. In control experiments, equal
amounts of dimethylsulfoxide or ethanol were added.
Cell proliferation analysis
A total of 2 × 104 cells per well were seeded in quadrupli-
cate in 24-well cell culture plates and were incubated with
nelfinavir for up to 4 days. The number of viable, trypan
blue-excluding cells was determined by a haemocytome-
ter.
MTT assay
For the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tet-
razolium bromide (MTT) assay analysis, 20 μl MTT
(Sigma) stock solution (5 mg/ml PBS) was added to viable
cells in 200 μl cell culture medium for 1 hour under cell
culture conditions. The water-insoluble precipitate was
dissolved in 100 μl dimethylsulfoxide and analysed by an
ELISA reader at 595 nm.
Annexin binding assay
FITC-labelled annexin V (Biocat, Heidelberg, Germany)
was applied to viable cells as recommended by the sup-
plier in combination with propidium iodide, and was
analysed by FACScan with an FL-1 setting (propidium
iodide) at 575 nm and an FL-2 setting (FITC) at 530 nm.
FACScan analysis was performed using a Becton Dickin-
son FACScan analyser (Becton Dickinson, Heidelberg,
Germany).
Western blot analysis
Cell extracts of cancer cells cultured in cell culture plates
were prepared with radio-immunoprecipitation buffer
(50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP40, 0.5% doxy-
choline, 0.1% SDS) and 20 μg protein (BioRad Bradford
Assay; BioRad, Munich, Germany) were subjected to
SDS-PAGE. Proteins were transferred to polyvinylidene
fluoride membranes in a BioRad Mini Protean II Cell
(BioRad) at 1 mA/cm2 membrane in 10% methanol, 192
mM glycine, 25 mM Tris, pH 8.2. Membranes were
blocked with 4% nonfat milk powder in PBS-0.05%
Tween for 4 hours. Primary antibodies were applied in
blocking buffer and incubated at room temperature over-
night.
Antibodies against poly(ADP-ribose) polymerase,
phospho-ERK1/2 (pp44/pp42), AKT, phospho-AKT, mcl-
1, IκB, and autophagy marker light chain 3B were all pur-
chased from Cell Signaling Technology (NEB, Frankfurt,
Germany). Antibodies against BiP (H-129), activating
transcription factor 3 (C-19) and β-actin (C4) were from
SantaCruz Biotech (Heidelberg, Germany). Secondary,Brüning et al. Breast Cancer Research 2010, 12:R45
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alkaline phosphatase-coupled antibodies against the cor-
responding primary antibodies were from Dianova
(Hamburg, Germany). Alkaline phosphatase detection
was performed either by the chromogenic BCIP/NBT
assay (Promega, Mannheim, Germany) or by the chemi-
luminescent alkaline phosphatase detection assay (Milli-
pore, Schwalbach, Germany), and the results were
analysed and documented using a BioRad QuantityOne
Image Analyzer and documentation software (BioRad).
Determination of intracellular glutathione levels
To detect intracellular glutathione levels, cells were
seeded in 96-well cell culture dishes and allowed to grow
for 24 hours under cell culture conditions. Cells were
then incubated with the cytotoxic drugs for up to 5 hours.
Intracellular glutathione levels were quantified using the
bioluminescent Promega GSH-Glo™ glutathione assay
(Promega), essentially as recommended by the supplier.
In brief, adherent cells were directly dissolved in 100 μl
GSH-Glo™ lysis and reaction buffer. After addition of 100
μl GSH-Glo™ Luciferin detection reagent, luminescence
was detected using a MicroLumat LB 96P bioluminome-
ter (EG&G Berthold, Bad Wildbad, Germany).
Determination of proteasomal activity
For the determination of cellular proteasome activity,
cells were seeded in 96-well cell culture dishes, allowed to
grow for 24 hours under cell culture conditions, and then
incubated with cytotoxic drugs for up to 5 hours. Protea-
somal activity was analysed using the bioluminescent
Promega Proteasome-Glo™ assay (Promega) as recom-
mended by the supplier. Adherent cells were directly dis-
solved in 50 μl Proteasome-Glo™ lysis and reagent buffer,
containing Suc-LLVY-aminoluciferin as a substrate. Leu-
kaemia cells were collected by centrifugation before lysis.
Bioluminescence was detected using a MicroLumat LB
96P bioluminometer (EG&G Berthold).
Statistical analysis
All experiments, except western blots and FACScan anal-
ysis, were performed in quadruplicate. The results were
evaluated using the nonparametric Wilcoxon sum test
and the Mann-Whitney U rank-sum test where applicable
(PASW version 17.0; SPSS Inc., Chigaco, IL, USA). Values
were plotted as the mean ± standard deviation, and sig-
nificance was assumed at P < 0.05 using the two-tailed
test. Significant relations are indicated in the figures and
the statistical test used is mentioned in the corresponding
figure legend.
Ethical aspects
All experiments were performed on established cancer
cell lines. No ethical approval or informed consent was
thus needed.
Results
Nelfinavir reduces cell proliferation of breast cancer cells 
and is able to induce apoptosis in breast cancer cells when 
applied at higher concentrations
The human breast cancer cell lines T47 D, MCF7, MDA-
MB-453, and MDA-MB-435 were incubated with nelfina-
vir at various concentrations with various time intervals
and were analysed for cell proliferation by counting viable
cells. Low doses of nelfinavir (5 μg/ml) reduced the cell
proliferation of breast cancer cells, and complete cell
death was achieved at a concentration of 15 μg/ml (Figure
1). Nelfinavir acted on oestrogen receptor-positive (T47
D, MCF7) as well as on oestrogen receptor-negative
(MDA-MB-453, MDA-MB-435) breast cancer cell lines.
Tamoxifen enhances the cytotoxic effect of nelfinavir
The mean plasma concentration of nelfinavir in HIV-
infected persons taking oral doses of nelfinavir was deter-
mined to be 2.2 μg/ml, reaching maximal plasma concen-
trations of up to 4 μg/ml [23,24]. These concentrations
can achieve only a partial reduction of breast cancer cell
proliferation (Figure 1), and are not efficient in inducing
apoptosis in breast cancer cells. The plasma concentra-
tion of nelfinavir, however, can be significantly increased
by administering higher oral doses of nelfinavir or by
intravenous application of nelfinavir [25]. Still, a possible
combination strategy of nelfinavir with other chemother-
apeutic drugs that would allow a reduction of single drug
concentrations would be advantageous.
When combining nelfinavir with tamoxifen, we
observed a substantially enhanced induction of cell death
even at lower nelfinavir concentrations (Figure 2). For
example, when used as a single agent, 6 μg/ml nelfinavir
induced only a slight and nonsignificant reduction of cell
viability by 6.1% in MCF7 cells and by 6.4% in T47 D cells
(Figure 2). Tamoxifen at 6 μg/ml reduced the cell viability
by 26.5% in MCF7 cells and by 40% in T47 D cells (Figure
2;  P  < 0.05). The combination of both nelfinavir and
tamoxifen, however, significantly reduced cell viability of
MCF7 cells and T47 D cells by up to 77.0% and 76.8%,
respectively (Figure 2; P < 0.05). FACScan analysis con-
firmed that the combination of 6 μg/ml nelfinavir with 6
μg/ml tamoxifen efficiently induced apoptosis in breast
cancer cells (Figure 3 and Table 1), although the same
concentrations proved to be insufficient for the induction
of apoptosis when used as single agents (Figure 3 and
Table 1).
Nelfinavir exerts pleiotropic proapoptotic and anti-
apoptotic effects in breast cancer cells
To gain a better insight into the cell death mechanism
induced by nelfinavir alone and in combination with
tamoxifen, W estern blot analyses of drug-treated breast
cancer cells were performed. First, the effects of nelfina-Brüning et al. Breast Cancer Research 2010, 12:R45
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vir as a single agent on breast cancer cells were analysed.
Using the cleavage of poly(ADP-ribose) polymerase as an
indicator of apoptosis, the specific induction of apoptosis
in breast cancer cells by high nelfinavir concentrations
(15 μg/ml) could be confirmed (Figure 4). Western blot-
ting further showed upregulation of BiP and activating
transcription factor 3 (ATF3) in nelfinavir-treated breast
cancer cells, indicating induction of endoplasmic reticu-
lum stress. Upregulation of BiP following nelfinavir treat-
ment, however, was scarcely detectable in MDA-MB-453
cells. In these cells, strong upregulation of autophagy
marker light chain 3B could be observed instead.
In all four cell lines, no change in the expression of the
proteasome-regulated NF-κB inhibitor IκB could be
observed, suggesting no influence of nelfinavir on the
proteasome activity in breast cancer cells. We have previ-
ously described an upregulation of the anti-apoptotic
mcl-1 protein by nelfinavir in ovarian cancer cells [26],
but this could only be observed in one (MDA-MB-435) of
the four tested breast cancer cell lines. Nelfinavir has fur-
ther been described as reducing AKT phosphorylation,
resulting in enhanced radiosensitivity [11,16] - which
could be of special importance for breast cancer treat-
ment, for which radiotherapy can be applied. We
observed no inhibition of AKT signalling in MCF7 and
T47 D cells by nelfinavir, however, and we even observed
a markedly enhanced AKT phosphorylation level in nelfi-
navir-treated MDA-MB-453 and MDA-MB-435 cells
(Figure 4).
Tamoxifen enhances the pleiotropic effects of nelfinavir in 
breast cancer cells
The effects of tamoxifen on the proapoptotic and anti-
apoptotic pathways that were induced by nelfinavir (Fig-
ure 4) were further investigated. Cell lysates of breast
cancer cells treated with 6 μg/ml nelfinavir or 6 μg/ml
Figure 1 Effect of nelfinavir on the cell survival of breast cancer cells. A total of 2 × 104 cells per well of the four indicated breast cancer cell lines 
were seeded in quadruplicate in 24-well cell culture plates, incubated with the indicated nelfinavir (NFV) concentrations, and the number of trypan 
blue-excluding cells was determined over a period of 4 days (d1 to d4). Values represent the mean ± standard deviation.Brüning et al. Breast Cancer Research 2010, 12:R45
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tamoxifen alone or in combination were subjected to
western blot analysis (Figure 5). Tamoxifen enhanced
upregulation of BiP in T47 D and MCF7 cells, and to a
lesser in MDA-MB-435 and MDA-MB-453 cells (Figure
5). In MDA-MB-453 cells, expression of the autophagy
marker light chain 3B was strongly enhanced. Tamoxifen,
nelfinavir, and its combination had no effect on AKT or
ERK phosphorylation in T47 D and MCF7 cells but, in
MDA-MB-435 and MDA-MB-453 cells, the combination
of tamoxifen with nelfinavir markedly enhanced AKT
phosphorylation (Figure 5).
Nelfinavir reduces glutathione levels in breast cancer cells
Tamoxifen has been reported to induce oxidative stress
[6]. Oxidative stress is reflected by or can be facilitated by
reduced intracellular glutathione levels, because glutathi-
one serves as an endogenous antioxidant and reduced
glutathione levels facilitate apoptosis [27]. When breast
cancer cells were incubated with tamoxifen or nelfinavir,
we observed that nelfinavir reduced glutathione levels in
breast cancer cells even more than tamoxifen did (Figure
6a). At a concentration of 6 μg/ml, nelfinavir reduced the
intracellular glutathione level of MCF7 and MDA-MB-
435 cells by 21.6% and 16.6%, respectively (P < 0.05). A
slight but statistically significant reduction of the gluta-
thione level by 7% (P < 0.05) could be observed for MCF7
cells treated with 6 μg/ml tamoxifen (Figure 6a). The
combination of 6 μg/ml nelfinavir with 6 μg/ml tamox-
ifen, however, did not further reduce the glutathione lev-
els in breast cancer cells in a significant manner (Figure
6a). Since the subtoxic concentration of 6 μg/ml nelfinavir
was already effective in reducing intracellular glutathione
levels, we tested the effect of nelfinavir at higher concen-
trations (20 μg/ml); these higher levels proved to be toxic
to all of the four breast cancer cell lines investigated. Fig-
ure 6b shows that 20 μg/ml nelfinavir reduced intracellu-
lar glutathione levels by up to 32.4% in MCF7 cells and by
30.1% in MDA-MB-435 cells.
The intracellular glutathione levels might vary not only
because of external drug applications, but likewise due to
differences in cell growth, nutrient concentrations (espe-
cially that of cysteine), and the redox state within the cells
or of the surrounding medium. These factors can vary
under cell culture conditions. Exogenously applied gluta-
thione or cysteine derivatives such as N-acetyl-cysteine
can enhance or replenish intracellular glutathione levels
or support the antioxidative effect of glutathione. To
analyse the involvement of glutathione depletion on nelfi-
navir-induced apoptosis, intracellular glutathione con-
tents were replenished by the addition of externally
applied glutathione or N-acetyl-cysteine. Figure 6c dem-
onstrates that the addition of glutathione, and even more
so the addition of N-acetyl-cysteine, can attenuate the
cytotoxic effect of nelfinavir on breast cancer cells. In the
absence of external glutathione or N-acetyl-cysteine, only
5% of the MCF7 cells and 12% of the MDA-MB-435 cells
survived the application of 15 μg/ml nelfinavir (Figure
6c). Although the addition of 5 mM glutathione was not
without negative effects on the cell viability of MCF7 cells
(Figure 6c), the presence of external glutathione
enhanced the remaining cell viability of MCF7 cells to
15% and to 17% in the case of MDA-MB-435 cells (Figure
6c). In the presence of 5 mM N-acetyl-cysteine, 18% of
the MCF7 cells remained viable, and up to 34% of the
MDA-MB-435 cells survived the addition of nelfinavir
(Figure 6c).
Table 1: Quantitative analysis of apoptotic and necrotic cells after tamoxifen and nelfinavir treatment
Cell line LL (%) UL (%) UR (%) LR (%)
T47D
Control 98.78 0.44 0.77 0.03
TAM 6 μg/ml 92.71 4.42 2.71 0.17
NFV 6 μg/ml 95.50 2.17 2.31 0.03
TAM/NFV 11.18 43.05 44.44 1.34
MCF7
Control 88.04 3.10 7.52 1.33
TAM 6 μg/ml 83.05 7.16 6.89 2.90
NFV 6 μg/ml 92.80 2.46 3.80 0.95
TAM/NFV 63.68 14.63 19.48 2.21
The relative cell distributions among the quadrants shown in Figure 2 were analysed using the BectonDickinson CellQuest software. LL, lower 
left (unstained; viable); UL, upper left (annexin-positive; apoptotic); UR, upper right (annexin-positive and propidium iodide-positive; 
apoptotic/necrotic); LR, lower right (propidium iodide permeable; necrotic); TAM, tamoxifen; NFV, nelfinavir.Brüning et al. Breast Cancer Research 2010, 12:R45
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Nelfinavir has no effect on the chymotrypsin-like 
proteasome activity of breast cancer cells
Some previous studies have indicated the inhibition of
proteasomal activity by HIV protease inhibitors, includ-
ing nelfinavir [26,28]. The fact that nelfinavir has no
influence on expression of the proteasome-regulated NF-
κB inhibitor IκB (Figure 4), however, indirectly suggests
that nelfinavir has no effect on the proteasomal activity of
breast cancer cells.
To clearly detect any influence of nelfinavir on protea-
somal activity in breast cancer cells, a direct, biolumines-
cent proteasome assay was performed. Bortezomib, a
specific proteasome inhibitor clinically approved for the
treatment of multiple myeloma, was used as a positive
control. Figure 7 shows that nelfinavir exerts no signifi-
cant effect on the chymotryptic proteasome activity in
MCF7 and MDA-MB-453 breast cancer cells. The effect
of bortezomib on the tested breast cancer cells was like-
wise poor, however, and 15 ng/ml bortezomib reduced
the chymotrypsin-like activity of the proteasome in
MCF7 cells by 37.5% and in T47 D cells by 17.9% only
(Figure 7). Under these conditions, but at even lower
bortezomib concentrations (4.5 ng/ml), a marked 89.6%
loss in cell viability could be observed in IM9 cells, a bort-
ezomib-sensitive lymphoblastoid cell line. Still, even in
IM9 cells, nelfinavir displayed no significant effect on the
chymotrypsin-like proteasome activity (Figure 7).
Discussion
The HIV protease inhibitor nelfinavir is a prospective
new anti-cancer drug, as shown by several in vitro as well
as in vivo studies [8-13]. The concentrations of nelfinavir
needed to induce cell death of cancer cells are higher than
those applied for HIV-infected individuals for HIV sup-
Figure 2 Combination effect of nelfinavir and tamoxifen on the cell survival of breast cancer cells. (a) A total of 5 × 103 MCF7 and T47 D cells 
per well were seeded in quadruplicate in 96-well cell culture plates, incubated with the indicated nelfinavir and tamoxifen (TAM) concentrations either 
alone or in combination, and were analysed for cell viability by an MTT assay after 72 hours of incubation. (b) A similar experiment was performed 
using different nelfinavir and TAM concentrations, and MTT-derived staining intensities were analysed by a photometer (shown as bar graphs). Values 
represent the mean ± standard deviation. Significance assumed at P < 0.05 with the nonparametric Wilcoxon rank-sum test.Brüning et al. Breast Cancer Research 2010, 12:R45
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pression, but this may be achieved by the application of
higher oral or intravenous doses of nelfinavir [25]. Still,
the prospects of nelfinavir as an anti-cancer drug will rely
less on its efficacy as a single drug and more on its ability
to cooperate with or sensitise to other chemotherapeutic
drugs or cancer treatment options. For example, we have
recently demonstrated that nelfinavir cooperates with the
multiple kinase inhibitor sorafenib to induce apoptosis in
various cancer cell types [26,29], and enhances TNF-
related apoptosis inducing ligand sensitivity in ovarian
cancer cells [30].
The present results show that the cytotoxic effects of
nelfinavir on breast cancer cells can be enhanced by com-
bination with tamoxifen, thus allowing the effective con-
c e n t r a t i o n  o f  n e l f i n a v i r  t o  b e  r e d u c e d .  T a m o x i f e n ,
although originally designed and applied as a selective
oestrogen receptor modulator, also represents a drug
with several described pleiotropic anti-tumoral effects
[6,7] - and two recent and independent studies observed
that tamoxifen is able to induce the endoplasmic reticu-
lum stress reaction [31,32], thus explaining the synergis-
tic effect of nelfinavir and tamoxifen on the induction of
endoplasmic reticulum stress. The nelfinavir-boosting
effect of tamoxifen was obviously independent of its abil-
ity to induce oxidative stress [6]. Instead, we observed
that nelfinavir itself reduced cellular glutathione levels,
indicating the occurrence of oxidative stress after nelfina-
vir treatment. Induction of oxidative stress occurs within
a few hours as an early effect of nelfinavir treatment and
has so far been neglected as an additional mechanism of
the pleiotropic anti-cancer effects of nelfinavir. The
observation that the effect of nelfinavir can be attenuated
by the addition of antioxidants (glutathione or N-acetyl-
cysteine) could have an impact on the efficacy of nelfina-
vir in cancer cells, as well as on the nelfinavir-induced
adverse effects occurring in HIV-infected persons.
Nelfinavir has been reported to exert a radiosensitising
effect by inhibiting proteasome activity and AKT signal-
ling [16]. Inhibition of proteasomal activity or AKT sig-
nalling in breast cancer cells, however, was not observed
in the present study. In contrast, nelfinavir markedly
enhanced AKT phosphorylation in some breast cancer
cell lines (MDA-MB-453 cells and MDA-MB-435 cells).
This observation is not surprising, however, since we pre-
viously demonstrated activation of the cell-protective
ERK1/2 signalling pathway by nelfinavir [26]. The endo-
plasmic stress reaction is primarily a cell-protective
mechanism, aiming to rescue cells from transient stress-
induced cell damage [21,33]. Longer exposure to cell
stress mechanisms or a cellular inability to cope with the
stress-induced cell damage then finally induces a switch
from cell protection to autophagy and apoptosis [21,33].
Endoplasmic reticulum stress has repeatedly been shown
to induce activation of both ERK1/2 and AKT signalling
Figure 3 Combination of nelfinavir and tamoxifen enhances apoptosis in breast cancer cells. The breast cancer cell lines MCF7 and T47 D were 
incubated with the indicated nelfinavir (NFV) and tamoxifen (TAM) concentrations either alone at 6 μg/ml or in combination (6 μg/ml NFV plus 6 μg/
ml TAM), and after 48 hours of incubation were analysed by FACScan analysis for the occurrence of apoptosis (FITC-annexin binding) and necrosis 
(propidium iodide permeability). FL-1 setting (propidium iodide; PJ), 575 nm; FL-2 setting (FITC), 530 nm.Brüning et al. Breast Cancer Research 2010, 12:R45
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[34-37]. Several studies, however, have likewise shown
that AKT activation, which can occur directly at the
endoplasmic reticulum [38], primarily represents a short-
term effect, and prolonged exposure of cells to endoplas-
mic reticulum stress indeed induces AKT inactivation
[38,39]. In fact, we observed a reduced AKT phosphory-
lation when breast cancer cells were treated with nelfina-
vir for more than 48 hours (data not shown), although
this indicates downregulation of AKT phosphorylation as
a secondary event. The present data therefore do not
exclude the potential use of nelfinavir as a radiosensitiser
even for breast cancer patients, but a potential negative
interaction between these two treatment options, espe-
cially shortly after nelfinavir application, should be kept
in mind.
In addition to the data on AKT signalling, the present
data revealed some other differences to previous studies
performed by us and other workers on different cancer
cell types. For example, upregulation of the anti-apop-
totic mcl-1 protein by nelfinavir - as we observed in ovar-
ian cancer cells [26] and leukaemia cells [29] - could only
be observed in a single breast cancer cell line (MDA-MB-
435 cells), and only at high concentrations of nelfinavir
(Figure 4). Further, we could not demonstrate proteasome
inhibition by nelfinavir in breast cancer cells.
Although nelfinavir induced cell death in all four breast
cancer cell lines tested, the data presented further indi-
cate that the cell lines respond quite differently to nelfina-
vir, especially regarding the effect on cell stress,
autophagy, and apoptosis. This variation might be due to
the different hormone receptor status of the cells, but
likewise may be due to the different malignancies of the
tumours from which these cell lines have been derived.
We therefore tried to include various types of breast can-
cer cell lines in the present study, ranging from hormone
receptor-positive breast cancer cells of a high differentia-
Figure 4 Treatment of breast cancer cells with nelfinavir activates 
pleiotropic pathways. The indicated four breast cancer cell lines were 
incubated with or without 15 μg/ml nelfinavir (NFV) for 48 hours and 
were analysed by Western blots for the expression and modification of 
cell survival-related proteins and pathways. PARP, poly(ADP-ribose) 
polymerase; BiP, binding protein; ATF3, activating transcription factor 
3; LC3B, autophagy marker light chain 3B.
Figure 5 Combination of nelfinavir and tamoxifen enhances the 
effect of nelfinavir-induced pathways. The oestrogen receptor-pos-
itive breast cancer cell lines MCF7 and T47 D and the oestrogen recep-
tor-negative breast cancer cell lines MDA-MB-435 and MDA-MB-453 
were incubated with the indicated nelfinavir (NFV) and tamoxifen 
(TAM) concentrations for 48 hours and were analysed by Western blot-
ting. Staining intensities of selected bands were analysed using a gel 
documentation system and program (BioRad Quantity One; BioRad, 
Munich, Germany), and were related to the corresponding β-actin ex-
pression value as an internal control (CON). For autophagy marker light 
chain 3B (LC3B) expression, the lower LC3B-II band was used for calcu-
lations. BiP, binding protein; T/N, tamoxifen and nelfinavir combina-
tion.Brüning et al. Breast Cancer Research 2010, 12:R45
http://breast-cancer-research.com/content/12/4/R45
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tion grade (T47 D cells) to highly de-differentiated hor-
mone receptor-negative breast cancer cells (MDA-MB-
435 cells). Interestingly, especially when low doses of nel-
finavir were applied, the de-differentiated hormone
receptor-negative breast cancer cell lines (MDA-MB-453
and MDA-MB-435 cells) appeared to react even better to
nelfinavir than the T47 D and MCF7 cells (Figure 1).
We observed that the combination of tamoxifen and
nelfinavir was able to induce cell death in oestrogen
receptor-positive as well as in oestrogen receptor-nega-
tive breast cancer cell lines. This indicates that both
oestrogen receptor-positive as well as oestrogen recep-
tor-negative breast cancer patients could benefit from a
combination of these two drugs.
Since both nelfinavir and tamoxifen have to be used at
concentrations higher than those used to inhibit the HIV
protease in HIV-infected persons or the oestrogen recep-
tor in hormone receptor-positive breast cancer patients,
however, care has to be taken that no unexpected adverse
effects occur - especially when both drugs, although dis-
playing moderate and tolerable adverse effects as single
agents, are combined. Further, the observed reduction in
glutathione levels by nelfinavir might cause an unex-
pected drug sensitisation in other tissues.
Figure 6 Nelfinavir, but not tamoxifen, induces glutathione reduction in breast cancer cells. (a) A total of 5 × 103 MCF7 and MDA-MB-435 cells 
per well were seeded in 96-well cell culture dishes and were incubated for 5 hours with either 6 μg/ml nelfinavir (NFV) or 6 μg/ml tamoxifen (TAM) 
alone or in combination (N/T). Intracellular glutathione levels were quantified using the bioluminescent Promega GSH-Glo™ glutathione assay (Pro-
mega, Mannheim, Germany). (b) MCF7 and MDA-MB-435 cells were incubated for 5 hours with the indicated NFV concentrations and were analysed 
for the cellular glutathione level as described in (a). (c) MCF7 and MDA-MB-435 cells were incubated with or without 15 μg/ml NFV for 72 hours in the 
presence or absence of 5 mM glutathione (GSH) or 5 mM N-acetyl-cysteine (NAC), and were analysed for cell survival by an MTT assay. Values represent 
the mean ± standard deviation. *Significance assumed at P < 0.05 with the nonparametric Mann-Whitney U rank-sum test. CON, control.Brüning et al. Breast Cancer Research 2010, 12:R45
http://breast-cancer-research.com/content/12/4/R45
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Clinical studies on breast cancer patients testing the
described combination of nelfinavir and tamoxifen are
thus of high interest in order to assess both efficacy and
safety of this drug combination.
Conclusions
The present study demonstrates the efficacy of nelfinavir
in breast cancer cells as a single agent, and a possible
combination treatment with tamoxifen. Both nelfinavir
and tamoxifen are already-approved drugs with known
pharmacokinetics, and they generally exhibit relative
mild and well tolerable adverse effects even after long-
term application. Since the concentrations of both drugs
have to be increased for an efficient cancer therapy, and a
combination of these two drugs has not yet been tested in
humans, however, it is important to first test the safety
and tolerability of this combination in phase I studies.
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